~~<i id='07225684AF'><strike id='07225684AF'><tt id='07225684AF'><pre id='07225684AF'></pre></tt></strike></i>~~

Home» focus» comprehensive

comprehensive

author：explore 2025-09-28 04:17:58 Page View：74676

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Can U.S. cancer drug shortages be fixed?
Next article： Supreme Court strikes down use of affirmative action

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Hospital at home shows how to bring innovation to health care

Acommunityparamedictakesthetemperatureofan88-year-oldpatientduringahomewellnesscheckinHawthorne,N.Y.

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

PBMs are inflating the cost of generic drugs. They must be reined in

AdobeThesearenotcomfortabledaysinWashingtonforpharmacybenefitmanagers,thehighlyconsolidatedgroupofin